Skip to main content
EJNMMI Research
Fig. 2 | EJNMMI Research

Fig. 2

From: Early prediction of treatment outcome for lenvatinib using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma refractory to radioiodine treatment: a prospective, multicentre, non-randomised study

Fig. 2

Imaging findings in 67-year-old patient with papillary carcinoma undergoing PET/CT and contrast-enhanced CT. At the initial treatment, PET/CT (a) and contrast-enhanced (b) showed a 2 cm primary tumour in the left thyroid with an SUVmax of 48.7. Systemic chemotherapy with a lenvatinib dose of 24 mg was initiated as the first-line therapy. After 1 week of treatment with lenvatinib, PET/CT (c) demonstrated a remarkable decline in SUVmax to 24.2. However, the mass is still visualised on contrast-enhanced CT (d) performed 4 weeks after treatment (arrow). At the time of writing this report, the patient was alive for more than 6 years after treatment. SUVmax: maximum standardised uptake value

Back to article page